J. Rick Turner

Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: A report from the Cardiac Safety Research Consortium

Jonathan Seltzer, J. Rick Turner, Mary Jane Geiger et al. · American Heart Journal · 2014 · 31 citations

Medicine, Cardiology, Pharmacology +12

The 50th Anniversary of the Kefauver‐Harris Amendments: Efficacy Assessment and the Randomized Clinical Trial

J. Rick Turner · Journal of Clinical Hypertension · 2012 · 15 citations · Full text

Medicine, Pharmacology, Clinical Pharmacology +10

FDA’s New Guidance for Industry Addressing Evaluation of the Safety of New Drugs for Improving Glycemic Control: A Case Study in Regulatory Science

J. Rick Turner · Therapeutic Innovation & Regulatory Science · 2020 · 14 citations · Full text

Pharmacy, Regulatory Pharmacy, Regulatory Policy +17

Identification of Risk of QT Prolongation by Pharmacists When Conducting Medication Reviews in Residential Aged Care Settings: A Missed Opportunity?

Louise Christensen, J. Rick Turner, Gregory M. Peterson et al. · Journal of Clinical Medicine · 2019 · 13 citations · Full text

Pharmacy, Geriatric Pharmacy, Pharmacy Practice +14

Individual‐Specific QT Interval Correction for Drugs With Substantial Heart Rate Effect Using Holter ECGs Extracted Over a Wide Range of Heart Rates

Gopi Krishna Panicker, Pramod Kadam, Saikat Chakraborty et al. · The Journal of Clinical Pharmacology · 2018 · 10 citations

Medicine, Cardiology, Pharmacology +13